Dr. Michael Hayden is one of the world’s leading experts in the genetic basis of movement disorders and CNS drug development. He recently served as President of Global R&D and Chief Scientific Officer at Teva.
05.29.18
Axovant Sciences announced that Gavin Corcoran, MB BCh, FACP, will join the Company as executive vice president of Research & Development, and Michael Hayden, MB ChB, PhD, FRSC, has been appointed as a senior scientific advisor to the company and chairman of Axovant’s newly established Scientific Advisory Board.
“I am pleased to welcome Gavin and Michael to the Axovant team,” said Pavan Cheruvu, MD, chief executive officer of Axovant. “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organization, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy. We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”
Dr. Gavin Corcoran has overseen successful drug development across multiple therapeutic areas including neurology and psychiatry. He currently serves as Chief Medical Officer at Allergan plc, and previously served as Chief Medical Officer of Actavis.
“I am pleased to welcome Gavin and Michael to the Axovant team,” said Pavan Cheruvu, MD, chief executive officer of Axovant. “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organization, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy. We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”
Dr. Gavin Corcoran has overseen successful drug development across multiple therapeutic areas including neurology and psychiatry. He currently serves as Chief Medical Officer at Allergan plc, and previously served as Chief Medical Officer of Actavis.
